Virus-derived anti-inflammatory proteins: Potential therapeutics for cancer

Trends in Molecular Medicine

Volumn 18, Issue 6, 2012, Pages 304-310

  Zheng, Donghang ^a   Chen, Hao ^a   Bartee, Mee Y ^a   Williams, Jennifer ^a,b   Davids, Jennifer A ^a   Huang, Emina ^a   Moreb, Jan ^a   Lucas, Alexandra ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cancer therapy; Chemokine binding proteins; Inflammation; M T1; M T7; Serp 1; Viral serpins

Indexed keywords

ANTINEOPLASTIC AGENT; SERINE PROTEINASE INHIBITOR; VIRUS PROTEIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CELL ACTIVATION; CELL INVASION; CELL PROLIFERATION; CHRONIC INFLAMMATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; METASTASIS; MICROENVIRONMENT; NONHUMAN; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINES; HUMANS; IMMUNOMODULATION; MICE; NEOPLASMS; PROTEIN BINDING; RECEPTORS, CHEMOKINE; SERPINS; VIRAL PROTEINS; VIRUSES;

EID: 84861850964     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.03.006     Document Type: Review

References (41)

1. Lucas A., et al. The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. Adv. Exp. Med. Biol. 2009, 666:132-156.
2. Dai E., et al. Inhibition of chemokine glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection. PLoS ONE 2010, 5:10510.
3. Tardif J.C., et al. A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circ. Cardiovasc. Interv. 2010, 3:543-548.
4. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
5. Mantovani A., et al. Cancer-related inflammation. Nature 2008, 454:436-444.
6. Kuraishy A., et al. Tumor promotion via injury- and death-induced inflammation. Immunity 2011, 35:467-477.
7. Davids J.A., et al. Viral anti-inflammatory proteins: the potential for immunotherapeutic application in cancer. Anti-inflamm. Anti-allergy Agents Med. Chem. 2008, 7:130-149.
8. Viswanathan K., et al. Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. J. Leukoc. Biol. 2009, 85:418-426.
9. Dai E., et al. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J. Biol. Chem. 2003, 278:18563-18572.
10. Richardson M., et al. Viral serpin, Serp-1, inhibits endogenous angiogenesis in the chicken chorioallantoic membrane (CAM) model. Cardiovasc. Pathol. 2007, 16:191-202.
11. Chu A.J. Blood coagulation as an intrinsic pathway for proinflammation: a mini review. Inflamm. Allergy Drug Targets 2010, 9:32-44.
12. Borensztajn K., et al. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol. Med. 2008, 14:429-440.
13. Franchini M., et al. Thrombin and cancer: from molecular basis to therapeutic implications. Semin. Thromb. Hemost. 2012, 38:95-101.
14. Hu L., et al. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004, 104:2746-2751.
15. Ulisse S., et al. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 2009, 9:32-71.
16. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb. Haemost. 2001, 86:324-333.
17. Hawinkels L.J., et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur. J. Cancer 2008, 44:1904-1913.
18. Mondino A., Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004, 25:450-455.
19. Cunningham O., et al. Dimerization controls the rapid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J. 2003, 22:5994-6003.
20. Madsen C.D., et al. uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 2007, 177:927-939.
21. Aguirre-Ghiso J.A., et al. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 2001, 12:863-879.
22. Tang C.H., et al. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with β1 integrins. J. Cell Sci. 2008, 121:3747-3756.
23. Wei Y., et al. Urokinase receptors are required for α5β1 integrin-mediated signaling in tumor cells. J. Biol. Chem. 2007, 282:3929-3939.
24. Smith H.W., et al. Regulation of cell signaling by uPAR. Nat. Rev. Mol. Cell Biol. 2010, 11:23-36.
25. Yoshizawa K. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: association with mode of invasion and clinicopathological factors. Oncol. Rep. 2011, 26:1555-1560.
26. Bailey C.M., et al. Biological functions of maspin. J. Cell Physiol. 2006, 209:617-624.
27. Viswanathan K., et al. Viral cross-class serpin inhibits apoptosis, inflammation and atherosclerosis. Modulation of Atherothrombotic Factors: Novel Strategies for Plaque Stabilization 2005, Print Partners Ipstamp, pp. 61-76.
28. Liu L., et al. Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation 2004, 77:1652-1660.
29. Liu J., et al. The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect. 2010, 12:1144-1152.
30. Boomker J.M., et al. The modulation of angiogenesis in the foreign body response by the poxviral protein M-T7. Biomaterials 2005, 26:4874-4881.
31. Seet B.T., McFadden G. Viral chemokine-binding proteins. J. Leukoc. Biol. 2002, 72:24-34.
32. Evanthia T., et al. Chemotaxis in cancer. Nat. Rev. Cancer 2011, 11:573-587.
33. Mantovani A., et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010, 21:27-39.
34. Lazennec G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 2010, 16:133-144.
35. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
36. Granot Z., et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20:300-314.
37. DeNardo D.G., et al. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010, 29:309-316.
38. Rozel S., et al. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J. Cell Biochem. 2009, 107:58-64.
39. Ito A., et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid. IL-2 Rγ(null) mouse model. Cancer Immunol. Immunother. 2009, 58:1195-1206.
40. Melnikova V.O., Bar-Eli M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res. 2006, 19:395-405.
41. Popivanova B.K., et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 2009, 69:7884-7892.